Оптимизация терапии в менопаузе у особых групп пациенток

1. Source: IQVIA, Ex-manufacturer prices in USD (ER=69), Standard units; Internal data: ADS SOP published.
2. Плавинский С.Л., Баринова А.Н., Озолиня Л.А. Нежелательные последствия использования гормональных средств. Анализ фармакоэпидемиологических исследований и баз спонтанных отчетов. Вопросы гинекологии, акушерства и перинатологии. 2019;18(6):92-9 [Plavinskii SL, Barinova AN, Ozolinia LA. Nezhelatel'nye posledstviia ispol'zovaniia gormonal'nykh sredstv. Analiz farmakoepidemiologicheskikh issledovanii i baz spontannykh otchetov. Voprosy ginekologii, akusherstva i perinatologii. 2019;18(6):92-9 (in Russian)]. DOI:10.20953/1726-1678-2019-6-92-99
3. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: World Health Organization; 2015.
4. Алгоритмы применения менопаузальной гормональной терапии у женщин в период пери- и постменопаузы. Совместная позиция экспертов РОАГ, РАМ, АГЭ, РАОП. Под ред. В.Н. Серова, С.В. Юреневой. Акушерство и гинекология. 2021;3:210-21 [Algoritmy primeneniia menopauzal'noi gormonal'noi terapii u zhenshchin v period peri- i postmenopauzy. Sovmestnaia pozitsiia ekspertov ROAG, RAM, AGE, RAOP. Pod red. VN Serova, SV Iurenevoi. Akusherstvo i ginekologiia. 2021;3:210-21 (in Russian)]. DOI:10.18565/aig.2021.3.210-221
5. Cho MK. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 2015;16:1061-70.
6. Beral V, Doll R, Hermon C, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371:303-14.
7. Bosetti C, Bravi F, Negri E, La Vecchia C. Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum Repr, 2009;15:489-98.
8. Оценка демографического, социального и экономического эффекта при приеме менопаузальной гормональной терапии. Оргздрав. 2020;4 [Otsenka demograficheskogo, sotsial'nogo i ekonomicheskogo effekta pri prieme menopauzal'noi gormonal'noi terapii. Orgzdrav. 2020;4 (in Russian)].
9. Baber RJ, Panay N, Fenton A и рабочая группа IMS. Рекомендации IMS 2016 г. по здоровью женщин зрелого возраста и менопаузальной гормональной терапии. Climacteric. 2016;19:109-50 [Baber RJ, Panay  N, Fenton A the IMS. Writing Group 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19:109-50 (in Russian)]. DOI:10.3109/13697137.2015.1129166
10. Munro MG; Southern California Permanente Medical Group’s Abnormal Uterine Bleeding Working Group. Investigation of women with postmenopausal uterine bleeding: clinical practice recommendations. Perm J. 2014;18(1):55-70.
11. Lou YY, Kannappar J, Sathiyathasan S. Unscheduled bleeding on HRT – do we always need to investigate for endometrial pathology? Int J Reprod, Contracept, Obstet Gynecol. 2017;6(10):4174-8. DOI:10.18203/2320-1770.ijrcog20174391
12. Carugno J. Clinical management of vaginal bleeding in postmenopausal women, Climacteric. 2020;23(4):343-9.
13. Clarke MA, Long BJ, Del Mar Morillo A, et al. Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis. JAMA Intern Med. 2018;178(9):1210-22.
14. Dave FG, Laiyemo R, Adedipe T. Unscheduled bleeding with hormone replacement therapy. Obstetrician Gynaecologist. 2019;21(2):95-101.
15. Sathiyathasan S, Kannappar J, Lou YY. Unscheduled bleeding on HRT – do we always need to investigate for endometrial pathology? Int J Reprod Contracept Obstet Gynecol. 2017;6(10):4174-8.
16. De Medeiros SF, Yamamoto MM, Barbosa JS. Abnormal bleeding during menopause hormone therapy: insights for clinical management. Clin Med Insights Womens Health. 2013;6:13-24.
17. Филиппова О.В. Фитоэстрогены: перспективы применения. Эффективная фармакотерапия. 2020;16(22):30-6 [Filippova O.V. Fitoestrogeny: perspektivy primeneniia. Effektivnaia farmakoterapiia. 2020;16(22):30-6 (in Russian)].
18. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM, Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology. 2000;141(10):3657-67.
19. Zhu W, Qin W, Zhang K, et al. Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr Cancer. 2012;64(3):393-400. DOI:10.1080/01635581.2012.654926
20. Leo L, Surico D, Deambrogio F, et al. Preliminary data on the effectiveness of resveratrol in a new formulation in treatment of hot flushes. Minerva Ginecol. 2015;67(5):475-83.
21. Davinelli S, Scapagnini G, Marzatico F, et al. Influence of equol and resveratrol supplementation on health-related quality of life in menopausal women: A randomized, placebo-controlled study. Maturitas. 2017;96:77-83. DOI:10.1016/j.maturitas.2016.11.016
22. Wong RHX, Evans HM, Howe PRC. Resveratrol supplementation reduces pain experience by postmenopausal women. Menopause. 2017;24(8):916-22.
23. Thaung Zaw JJ, Howe PRC, Wong RHX. Long-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women: findings from a 24-month randomized, controlled, crossover trial. Menopause. 2020;28(1):40-9.
24. Milia R. Improvement of climacteric symptoms with a novel sublingual product containing transresveratrol. Progr Nutr. 2015;17(1):68-72.
25. Uberti F, Morsanuto V, Aprile S, et al. Biological effects of combined resveratrol and vitamin D3 on ovarian tissue. J Ovar Res. 2017;10:61.
26. Liel Y, Kraus S, Levy J, Shany S. Evidence that estrogens modulate activity and increase the number of 1,25-dihydroxyvitamin D receptors in osteoblast-like cells. Endocrinology. 1992;130 (5):2597-601.
27. Bhat KP, Kosmeder JW, Pezzuto JM. Biological effects of resveratrol. Antioxid Redox Signal. 2001;3(6):1041-64.
28. Das S, Mitrovsky G, Vasanthi HR, et al. Antiaging Properties of a Grape-Derived Antioxidant Are Regulated by Mitochondrial Balance of Fusion and Fission Leading to Mitophagy Triggered by a Signaling Network of Sirt1-Sirt3-Foxo3-PINK1-PARKIN. Oxid Med Cell Longev. 2014;2014:345105.
29. Wong RHX, Thaung Zaw JJ, Xian CJ, Howe PRC. Regular supplementation with resveratrol improves bone mineral density in postmenopausal women: A randomized, placebo-controlled trial. J Bone Min Res 2020;35(11):2121-213. DOI:10.1002/jbmr.4115
30. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337-42.
31. Elliott PJ, Walpole S, Morelli L, et al. Resveratrol/SRT501. Sirtuin SIRT1 activator, Treatment of type 2 diabetes. Drugs Fut. 2009;34:291-5.
32. Wang Z, Zou J, Huang Y et al. Effect of resveratrol on platelet aggregation in vivo and in vitro. Chin Med J (Engl). 2002;115 (3):378-80.
33. Williams LD, Burdock GA, Edwards JA, et al. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol. 2009;49:2170-221.
34. Fratter A, Semenzato A. New association of surfactants for the production of food and cosmetic nanoemulsions: preliminary development and characterization. Int J Cosmetic Sci. 2011;33(5):443-9.

________________________________________________

1. Source: IQVIA, Ex-manufacturer prices in USD (ER=69), Standard units; Internal data: ADS SOP published.
2. Plavinskii SL, Barinova AN, Ozolinia LA. Nezhelatel'nye posledstviia ispol'zovaniia gormonal'nykh sredstv. Analiz farmakoepidemiologicheskikh issledovanii i baz spontannykh otchetov. Voprosy ginekologii, akusherstva i perinatologii. 2019;18(6):92-9 (in Russian). DOI:10.20953/1726-1678-2019-6-92-99
3. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: World Health Organization; 2015.
4. Algoritmy primeneniia menopauzal'noi gormonal'noi terapii u zhenshchin v period peri- i postmenopauzy. Sovmestnaia pozitsiia ekspertov ROAG, RAM, AGE, RAOP. Pod red. VN Serova, SV Iurenevoi. Akusherstvo i ginekologiia. 2021;3:210-21 (in Russian). DOI:10.18565/aig.2021.3.210-221
5. Cho MK. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 2015;16:1061-70.
6. Beral V, Doll R, Hermon C, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371:303-14.
7. Bosetti C, Bravi F, Negri E, La Vecchia C. Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum Repr, 2009;15:489-98.
8. Otsenka demograficheskogo, sotsial'nogo i ekonomicheskogo effekta pri prieme menopauzal'noi gormonal'noi terapii. Orgzdrav. 2020;4 (in Russian).
9. Baber RJ, Panay  N, Fenton A the IMS. Writing Group 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19:109-50 (in Russian). DOI:10.3109/13697137.2015.1129166
10. Munro MG; Southern California Permanente Medical Group’s Abnormal Uterine Bleeding Working Group. Investigation of women with postmenopausal uterine bleeding: clinical practice recommendations. Perm J. 2014;18(1):55-70.
11. Lou YY, Kannappar J, Sathiyathasan S. Unscheduled bleeding on HRT – do we always need to investigate for endometrial pathology? Int J Reprod, Contracept, Obstet Gynecol. 2017;6(10):4174-8. DOI:10.18203/2320-1770.ijrcog20174391
12. Carugno J. Clinical management of vaginal bleeding in postmenopausal women, Climacteric. 2020;23(4):343-9.
13. Clarke MA, Long BJ, Del Mar Morillo A, et al. Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis. JAMA Intern Med. 2018;178(9):1210-22.
14. Dave FG, Laiyemo R, Adedipe T. Unscheduled bleeding with hormone replacement therapy. Obstetrician Gynaecologist. 2019;21(2):95-101.
15. Sathiyathasan S, Kannappar J, Lou YY. Unscheduled bleeding on HRT – do we always need to investigate for endometrial pathology? Int J Reprod Contracept Obstet Gynecol. 2017;6(10):4174-8.
16. De Medeiros SF, Yamamoto MM, Barbosa JS. Abnormal bleeding during menopause hormone therapy: insights for clinical management. Clin Med Insights Womens Health. 2013;6:13-24.
17. Filippova O.V. Fitoestrogeny: perspektivy primeneniia. Effektivnaia farmakoterapiia. 2020;16(22):30-6 (in Russian).
18. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM, Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology. 2000;141(10):3657-67.
19. Zhu W, Qin W, Zhang K, et al. Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr Cancer. 2012;64(3):393-400. DOI:10.1080/01635581.2012.654926
20. Leo L, Surico D, Deambrogio F, et al. Preliminary data on the effectiveness of resveratrol in a new formulation in treatment of hot flushes. Minerva Ginecol. 2015;67(5):475-83.
21. Davinelli S, Scapagnini G, Marzatico F, et al. Influence of equol and resveratrol supplementation on health-related quality of life in menopausal women: A randomized, placebo-controlled study. Maturitas. 2017;96:77-83. DOI:10.1016/j.maturitas.2016.11.016
22. Wong RHX, Evans HM, Howe PRC. Resveratrol supplementation reduces pain experience by postmenopausal women. Menopause. 2017;24(8):916-22.
23. Thaung Zaw JJ, Howe PRC, Wong RHX. Long-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women: findings from a 24-month randomized, controlled, crossover trial. Menopause. 2020;28(1):40-9.
24. Milia R. Improvement of climacteric symptoms with a novel sublingual product containing transresveratrol. Progr Nutr. 2015;17(1):68-72.
25. Uberti F, Morsanuto V, Aprile S, et al. Biological effects of combined resveratrol and vitamin D3 on ovarian tissue. J Ovar Res. 2017;10:61.
26. Liel Y, Kraus S, Levy J, Shany S. Evidence that estrogens modulate activity and increase the number of 1,25-dihydroxyvitamin D receptors in osteoblast-like cells. Endocrinology. 1992;130 (5):2597-601.
27. Bhat KP, Kosmeder JW, Pezzuto JM. Biological effects of resveratrol. Antioxid Redox Signal. 2001;3(6):1041-64.
28. Das S, Mitrovsky G, Vasanthi HR, et al. Antiaging Properties of a Grape-Derived Antioxidant Are Regulated by Mitochondrial Balance of Fusion and Fission Leading to Mitophagy Triggered by a Signaling Network of Sirt1-Sirt3-Foxo3-PINK1-PARKIN. Oxid Med Cell Longev. 2014;2014:345105.
29. Wong RHX, Thaung Zaw JJ, Xian CJ, Howe PRC. Regular supplementation with resveratrol improves bone mineral density in postmenopausal women: A randomized, placebo-controlled trial. J Bone Min Res 2020;35(11):2121-213. DOI:10.1002/jbmr.4115
30. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337-42.
31. Elliott PJ, Walpole S, Morelli L, et al. Resveratrol/SRT501. Sirtuin SIRT1 activator, Treatment of type 2 diabetes. Drugs Fut. 2009;34:291-5.
32. Wang Z, Zou J, Huang Y et al. Effect of resveratrol on platelet aggregation in vivo and in vitro. Chin Med J (Engl). 2002;115 (3):378-80.
33. Williams LD, Burdock GA, Edwards JA, et al. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol. 2009;49:2170-221.
34. Fratter A, Semenzato A. New association of surfactants for the production of food and cosmetic nanoemulsions: preliminary development and characterization. Int J Cosmetic Sci. 2011;33(5):443-9.

________________________________________________

1. Source: IQVIA, Ex-manufacturer prices in USD (ER=69), Standard units; Internal data: ADS SOP published.
2. Plavinskii SL, Barinova AN, Ozolinia LA. Nezhelatel'nye posledstviia ispol'zovaniia gormonal'nykh sredstv. Analiz farmakoepidemiologicheskikh issledovanii i baz spontannykh otchetov. Voprosy ginekologii, akusherstva i perinatologii. 2019;18(6):92-9 (in Russian). DOI:10.20953/1726-1678-2019-6-92-99
3. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: World Health Organization; 2015.
4. Algoritmy primeneniia menopauzal'noi gormonal'noi terapii u zhenshchin v period peri- i postmenopauzy. Sovmestnaia pozitsiia ekspertov ROAG, RAM, AGE, RAOP. Pod red. VN Serova, SV Iurenevoi. Akusherstvo i ginekologiia. 2021;3:210-21 (in Russian). DOI:10.18565/aig.2021.3.210-221
5. Cho MK. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 2015;16:1061-70.
6. Beral V, Doll R, Hermon C, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371:303-14.
7. Bosetti C, Bravi F, Negri E, La Vecchia C. Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum Repr, 2009;15:489-98.
8. Otsenka demograficheskogo, sotsial'nogo i ekonomicheskogo effekta pri prieme menopauzal'noi gormonal'noi terapii. Orgzdrav. 2020;4 (in Russian).
9. Baber RJ, Panay N, Fenton A и рабочая группа IMS. Рекомендации IMS 2016 г. по здоровью женщин зрелого возраста и менопаузальной гормональной терапии. Climacteric. 2016;19:109-50 [Baber RJ, Panay  N, Fenton A the IMS. Writing Group 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19:109-50 (in Russian)]. DOI:10.3109/13697137.2015.1129166
10. Munro MG; Southern California Permanente Medical Group’s Abnormal Uterine Bleeding Working Group. Investigation of women with postmenopausal uterine bleeding: clinical practice recommendations. Perm J. 2014;18(1):55-70.
11. Lou YY, Kannappar J, Sathiyathasan S. Unscheduled bleeding on HRT – do we always need to investigate for endometrial pathology? Int J Reprod, Contracept, Obstet Gynecol. 2017;6(10):4174-8. DOI:10.18203/2320-1770.ijrcog20174391
12. Carugno J. Clinical management of vaginal bleeding in postmenopausal women, Climacteric. 2020;23(4):343-9.
13. Clarke MA, Long BJ, Del Mar Morillo A, et al. Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis. JAMA Intern Med. 2018;178(9):1210-22.
14. Dave FG, Laiyemo R, Adedipe T. Unscheduled bleeding with hormone replacement therapy. Obstetrician Gynaecologist. 2019;21(2):95-101.
15. Sathiyathasan S, Kannappar J, Lou YY. Unscheduled bleeding on HRT – do we always need to investigate for endometrial pathology? Int J Reprod Contracept Obstet Gynecol. 2017;6(10):4174-8.
16. De Medeiros SF, Yamamoto MM, Barbosa JS. Abnormal bleeding during menopause hormone therapy: insights for clinical management. Clin Med Insights Womens Health. 2013;6:13-24.
17. Filippova O.V. Fitoestrogeny: perspektivy primeneniia. Effektivnaia farmakoterapiia. 2020;16(22):30-6 (in Russian).
18. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM, Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology. 2000;141(10):3657-67.
19. Zhu W, Qin W, Zhang K, et al. Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr Cancer. 2012;64(3):393-400. DOI:10.1080/01635581.2012.654926
20. Leo L, Surico D, Deambrogio F, et al. Preliminary data on the effectiveness of resveratrol in a new formulation in treatment of hot flushes. Minerva Ginecol. 2015;67(5):475-83.
21. Davinelli S, Scapagnini G, Marzatico F, et al. Influence of equol and resveratrol supplementation on health-related quality of life in menopausal women: A randomized, placebo-controlled study. Maturitas. 2017;96:77-83. DOI:10.1016/j.maturitas.2016.11.016
22. Wong RHX, Evans HM, Howe PRC. Resveratrol supplementation reduces pain experience by postmenopausal women. Menopause. 2017;24(8):916-22.
23. Thaung Zaw JJ, Howe PRC, Wong RHX. Long-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women: findings from a 24-month randomized, controlled, crossover trial. Menopause. 2020;28(1):40-9.
24. Milia R. Improvement of climacteric symptoms with a novel sublingual product containing transresveratrol. Progr Nutr. 2015;17(1):68-72.
25. Uberti F, Morsanuto V, Aprile S, et al. Biological effects of combined resveratrol and vitamin D3 on ovarian tissue. J Ovar Res. 2017;10:61.
26. Liel Y, Kraus S, Levy J, Shany S. Evidence that estrogens modulate activity and increase the number of 1,25-dihydroxyvitamin D receptors in osteoblast-like cells. Endocrinology. 1992;130 (5):2597-601.
27. Bhat KP, Kosmeder JW, Pezzuto JM. Biological effects of resveratrol. Antioxid Redox Signal. 2001;3(6):1041-64.
28. Das S, Mitrovsky G, Vasanthi HR, et al. Antiaging Properties of a Grape-Derived Antioxidant Are Regulated by Mitochondrial Balance of Fusion and Fission Leading to Mitophagy Triggered by a Signaling Network of Sirt1-Sirt3-Foxo3-PINK1-PARKIN. Oxid Med Cell Longev. 2014;2014:345105.
29. Wong RHX, Thaung Zaw JJ, Xian CJ, Howe PRC. Regular supplementation with resveratrol improves bone mineral density in postmenopausal women: A randomized, placebo-controlled trial. J Bone Min Res 2020;35(11):2121-213. DOI:10.1002/jbmr.4115
30. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337-42.
31. Elliott PJ, Walpole S, Morelli L, et al. Resveratrol/SRT501. Sirtuin SIRT1 activator, Treatment of type 2 diabetes. Drugs Fut. 2009;34:291-5.
32. Wang Z, Zou J, Huang Y et al. Effect of resveratrol on platelet aggregation in vivo and in vitro. Chin Med J (Engl). 2002;115 (3):378-80.
33. Williams LD, Burdock GA, Edwards JA, et al. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol. 2009;49:2170-221.
34. Fratter A, Semenzato A. New association of surfactants for the production of food and cosmetic nanoemulsions: preliminary development and characterization. Int J Cosmetic Sci. 2011;33(5):443-9.